Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A Hoosier Oncology Group trial

Gura Sonpavde, Rafat Ansari, Paul Walker, David F. Sciortino, G. Thomas Gabrys, Ann Murdock, René Gonin, Lawrence Einhorn

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2 followed by paclitaxel 175 mg/m2 over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well- tolerated with grade III neurotoxicity in 5 patients (11%), grade III/IV emesis in 5 (11%), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63%) had grade IV and 8 (17%) grade III granulocytopenia. Nine patients (20%) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41%) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52%) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).

Original languageEnglish
Pages (from-to)68-70
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number1
DOIs
StatePublished - Feb 2000

Fingerprint

Small Cell Lung Carcinoma
Paclitaxel
Doxorubicin
Drug Therapy
Disease Progression
Mucositis
Agranulocytosis
Myalgia
Vomiting
Fever
Therapeutics
Mortality

Keywords

  • Doxorubicin
  • Paclitaxel
  • Second-line chemotherapy
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer : A Hoosier Oncology Group trial. / Sonpavde, Gura; Ansari, Rafat; Walker, Paul; Sciortino, David F.; Gabrys, G. Thomas; Murdock, Ann; Gonin, René; Einhorn, Lawrence.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 1, 02.2000, p. 68-70.

Research output: Contribution to journalArticle

Sonpavde, Gura ; Ansari, Rafat ; Walker, Paul ; Sciortino, David F. ; Gabrys, G. Thomas ; Murdock, Ann ; Gonin, René ; Einhorn, Lawrence. / Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer : A Hoosier Oncology Group trial. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2000 ; Vol. 23, No. 1. pp. 68-70.
@article{0860453eb41f400d84bb7c4b72a3a836,
title = "Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A Hoosier Oncology Group trial",
abstract = "Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2 followed by paclitaxel 175 mg/m2 over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well- tolerated with grade III neurotoxicity in 5 patients (11{\%}), grade III/IV emesis in 5 (11{\%}), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63{\%}) had grade IV and 8 (17{\%}) grade III granulocytopenia. Nine patients (20{\%}) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41{\%}) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52{\%}) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).",
keywords = "Doxorubicin, Paclitaxel, Second-line chemotherapy, Small-cell lung cancer",
author = "Gura Sonpavde and Rafat Ansari and Paul Walker and Sciortino, {David F.} and Gabrys, {G. Thomas} and Ann Murdock and Ren{\'e} Gonin and Lawrence Einhorn",
year = "2000",
month = "2",
doi = "10.1097/00000421-200002000-00019",
language = "English",
volume = "23",
pages = "68--70",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer

T2 - A Hoosier Oncology Group trial

AU - Sonpavde, Gura

AU - Ansari, Rafat

AU - Walker, Paul

AU - Sciortino, David F.

AU - Gabrys, G. Thomas

AU - Murdock, Ann

AU - Gonin, René

AU - Einhorn, Lawrence

PY - 2000/2

Y1 - 2000/2

N2 - Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2 followed by paclitaxel 175 mg/m2 over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well- tolerated with grade III neurotoxicity in 5 patients (11%), grade III/IV emesis in 5 (11%), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63%) had grade IV and 8 (17%) grade III granulocytopenia. Nine patients (20%) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41%) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52%) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).

AB - Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2 followed by paclitaxel 175 mg/m2 over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well- tolerated with grade III neurotoxicity in 5 patients (11%), grade III/IV emesis in 5 (11%), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63%) had grade IV and 8 (17%) grade III granulocytopenia. Nine patients (20%) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41%) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52%) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).

KW - Doxorubicin

KW - Paclitaxel

KW - Second-line chemotherapy

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0034094187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034094187&partnerID=8YFLogxK

U2 - 10.1097/00000421-200002000-00019

DO - 10.1097/00000421-200002000-00019

M3 - Article

C2 - 10683082

AN - SCOPUS:0034094187

VL - 23

SP - 68

EP - 70

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -